Meeting
2018 ASCO Annual Meeting
Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.
Authors
Cornelia Liedtke
Charité - Universitätsmedizin Berlin, Berlin, Germany
Cornelia Liedtke , Friedrich Feuerhake , Madlen Garke , Matthias Christgen , Ronald E. Kates , Eva-Maria Grischke , Helmut Forstbauer , Michael Wilhelm Braun , Mathias R. Warm , Christoph Hackmann , Christoph Uleer , Bahriye Aktas , Claudia Schumacher , Sherko Kummel , Rachel Wuerstlein , Ulrike Nitz , Hans Heinrich Kreipe , Oleg Gluz , Nadia Harbeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor-Based Biomarkers
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12102)
DOI
10.1200/JCO.2018.36.15_suppl.12102
Abstract #
12102
Poster Bd #
215
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).
First Author: Lisa Katharina Katharina Richters
Poster
2016 ASCO Annual Meeting
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).
First Author: Sherko Kümmel
Poster
2018 ASCO Annual Meeting
Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.
First Author: Oleg Gluz
Poster
2017 ASCO Annual Meeting
Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.
First Author: Oleg Gluz